A Phase I Study of the P13-Kinase Inhibitor BKM120 in Combination with Docetaxel in Patients with Advanced Solid Tumors
Description: 

The purpose of the study is to find the highest dose of an investigational drug BKM120 that can be given to patients with cancer in combination with commonly used chemotherapy drug Docetaxel without causing severe side effects.

Study Number: 

I 186510

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01540253

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.